Last reviewed · How we verify
standard treatment COVID-19 + Triazavirin
standard treatment COVID-19 + Triazavirin is a Nucleoside analog antiviral Small molecule drug developed by Ain Shams University. It is currently FDA-approved for COVID-19 (in combination with standard treatment). Also known as: standard treatment COVID-19 + Oseltamivir.
Triazavirin is a nucleoside analog that inhibits viral RNA polymerase to reduce SARS-CoV-2 replication.
Triazavirin is a nucleoside analog that inhibits viral RNA polymerase to reduce SARS-CoV-2 replication. Used for COVID-19 (in combination with standard treatment).
At a glance
| Generic name | standard treatment COVID-19 + Triazavirin |
|---|---|
| Also known as | standard treatment COVID-19 + Oseltamivir |
| Sponsor | Ain Shams University |
| Drug class | Nucleoside analog antiviral |
| Target | Viral RNA-dependent RNA polymerase (RdRp) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Triazavirin acts as a broad-spectrum antiviral by mimicking nucleosides and interfering with viral RNA-dependent RNA polymerase, thereby blocking viral genome replication. When combined with standard COVID-19 treatment protocols, it is intended to enhance antiviral efficacy and reduce viral load in infected patients.
Approved indications
- COVID-19 (in combination with standard treatment)
Common side effects
- Gastrointestinal disturbances
- Elevated liver enzymes
- Hematologic abnormalities
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard treatment COVID-19 + Triazavirin CI brief — competitive landscape report
- standard treatment COVID-19 + Triazavirin updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about standard treatment COVID-19 + Triazavirin
What is standard treatment COVID-19 + Triazavirin?
How does standard treatment COVID-19 + Triazavirin work?
What is standard treatment COVID-19 + Triazavirin used for?
Who makes standard treatment COVID-19 + Triazavirin?
Is standard treatment COVID-19 + Triazavirin also known as anything else?
What drug class is standard treatment COVID-19 + Triazavirin in?
What development phase is standard treatment COVID-19 + Triazavirin in?
What are the side effects of standard treatment COVID-19 + Triazavirin?
What does standard treatment COVID-19 + Triazavirin target?
Related
- Drug class: All Nucleoside analog antiviral drugs
- Target: All drugs targeting Viral RNA-dependent RNA polymerase (RdRp)
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for COVID-19 (in combination with standard treatment)
- Also known as: standard treatment COVID-19 + Oseltamivir
- Compare: standard treatment COVID-19 + Triazavirin vs similar drugs
- Pricing: standard treatment COVID-19 + Triazavirin cost, discount & access